ArticleNeurochemical research2026
Neuroprotective Effects of lncRNA EPB41L4A-AS1 Against Ischemic Stroke Injury Through Regulating Microglial State Transition and Ferroptosis via miR-214-3p/GPX4 Axis.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) regulate microRNAs and their target genes to control key pathological processes after acute ischemic stroke (AIS). To investigate lncRNA EPB41L4A-AS1's role in microglial function via miR-214-3p/GPX4, and its clinical relevance as a prognostic indicator in AIS. EPB41L4A-AS1 levels were measured by RT-qPCR in 120 AIS patients and OGD/R-treated BV2 microglia. ELISA and western blot were employed to assess microglial state transition and ferroptosis in OGD/R-injured BV2 cells. A combination of RIP, RNA pull-down, and luciferase reporter assays were employed to validate the miRNA and gene targets regulated by EPB41L4A-AS1. Functional rescue assays were conducted by co-transfecting miR-214-3p with GPX4 to validate the regulatory relationship in vitro. EPB41L4A-AS1 was significantly downregulated in the serum of AIS patients, with lower levels predicting worse prognosis. Elevated EPB41L4A-AS1 expression substantially reduced pro-inflammatory markers (iNOS, TL-1β and TNF-α), but enhanced anti-inflammatory markers (Arg1 and IL-10) of OGD/R-injured BV2 cells. Meanwhile, the iron overload and lipid peroxidation in OGD/R cells were also improved. RIP, RNA pull-down, and luciferase reporter assays confirmed the specific binding of miR-214-3p to EPB41L4A-AS1 and GPX4. Upon EPB41L4A-AS1 overexpression, miR-214-3p mimic amplified the iron overload and oxidative stress and led to a pro-inflammatory state of BV2 cells under OGD/R conditions. Restoring GPX4 expression abrogated these observed effects. Lower serum EPB41L4A-AS1 correlates with poor prognosis in AIS patients. The mechanism underlying its neuroprotective effects against microglial state transition and ferroptosis was delineated through the miR-214-3p/GPX4 axis.
Indexed as
Identifiers
42430067What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.